Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
P/E ratio for Outlook Therapeutics, Inc. (OTLK)
P/E ratio as of 2023: -0.94
According to Outlook Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.94. At the end of 2022 the company had a P/E ratio of -3.92.
P/E ratio history for Outlook Therapeutics, Inc. from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.94 |
| 2022 | -3.92 |
| 2021 | -6.23 |
| 2020 | -1.48 |
| 2019 | -0.79 |
| 2018 | -3.09 |
| 2017 | -0.85 |
| 2016 | -1.37 |
| 2015 | -1.35 |
| 2014 | -4.40 |